Scientists have found that glucose plays a significant role in how the brain functions.

FTC Sues Leading Transgender Health Group

The suit alleges the group made deceptive claims about gender-affirming care for minors

Lifestyle Treatments as Important as Medications in Managing Obesity in Kids, Teens

Semaglutide combined with counseling "emerged as the most potent intervention"

White House Denies Trump Got Unapproved Obesity Drug

Compassionate use of retatrutide granted for someone with sleep apnea, pulmonary hypertension

Hospitals in Blue States Continue to Drop Gender-Affirming Care for Youths

One private clinic took on hundreds of patients after health systems stopped

Are People With Eating Disorders Misusing GLP-1 Drugs?

This group may be taking the weight-loss drugs in contraindicated ways, researchers suggest

Few IVF Add-Ons Have Any Proven Benefits, Study Shows

An evidence-based website could help patients better understand these treatments

Democrats Press Trump Admin on Special Access to Obesity Drug

If not the president, then who, senator asks

988's LGBTQ+ Hotline Is Relaunching. The Group That Helped Start It May Be Excluded.

Leaving the organization out is raising concerns about the relaunched service

Oral FGFR1-3 Inhibitor Boosted Height Velocity in Common Genetic Growth Disorder

Drug has different mechanism of action than existing injectables

New Drug Approved for Thyroid Eye Disease

Veligrotug labeling shows data for both the active and chronic forms of TED

ADA Video Pearls: Video Pearls from the American Diabetes Association

ENDO Video Pearls: Video Pearls from The Endocrine Society

GLP-1s After Surgery; Retatrutide for Pulmonary Hypertension? Vit D for Prediabetes

News and commentary from the endocrinology world

Diabetes Drug Class Tied to Lower Dementia Risk in People With Psych Disorders

SGLT2 inhibitor use also correlated with lower rates of psychiatric ED visits

Medicare Is Now Covering Some GLP-1s for Weight-Loss for $50. Here's What to Know

— Only some of the medications are included

Positive Phase 2 Results for New Oral GLP-1 for Obesity

A US-based phase 2 trial of an investigational oral GLP-1 called CX11 shows up to 11.5% weight loss and a favorable safety profile among patients living with obesity.